%0 Journal Article
%T Dura mater mitral and tricuspid bioprostheses: 30 years of follow-up
%A Puig
%A Luiz Boro
%A Brand£¿o
%A Carlos Manuel de Almeida
%A Kawabe
%A Lauro
%A Verginelli
%A Geraldo
%A Ramires
%A Jos¨¦ Antonio Francchini
%A Oliveira
%A S¨¦rgio Almeida de
%J Revista do Hospital das Cl¨ªnicas
%D 2003
%I Scientific Electronic Library Online
%R 10.1590/S0041-87812003000300006
%X purpose: the dura mater bioprosthesis was developed in the department of cardiopneumology of the hospital das cl¨ªnicas of the university of s£¿o paulo medical school in 1971. here, we present the clinical results of the dura mater bioprosthesis over 30 years of follow-up. methods: we studied 70 consecutive patients who underwent mitral or tricuspid valve replacement with a dura mater bioprosthesis between january 1971 and august 1972. results: the early mortality was 10% (7 patients). the follow-up was 87% complete (9 patients were lost to follow-up). two patients were alive and asymptomatic 30 years after valve replacement; 33 patients underwent reoperations due to valve dysfunction, and 19 died during the follow-up period. at 30 years, the actuarial survival was 49.2 ¡À 8.6%; freedom from rupture, 27.0 ¡À 10.2%; freedom from calcification, 78.8 ¡À 8.6%; and freedom from reoperation, 18.8 ¡À 7.5%. conclusions: the dura mater bioprosthesis played an important role in the treatment of patients with mitral and tricuspid valve disease. the low rate of thromboembolism and the long period of follow-up without evidence of valve dysfunction, which occurred for several of our patients, are important characteristics of these bioprosthesis.
%K dura mater
%K bioprosthesis
%K glycerol
%K valve disease
%K valve surgery.
%U http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0041-87812003000300006&lng=en&nrm=iso&tlng=en